Creating EU-CTR compliant and patient-friendly lay language summaries (LLS)
Related Insights
Blog
Breaking through complex regulations and science speak – thinking “patients first” in lay language summary development
Jun 22, 2021
Blog
New FDA draft guidance: Implications for simplifying interchangeability for biosimilars in the US
Jul 16, 2024
Article
Q&A Project Optimus: What you need to know
Oct 11, 2022
Article
New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle
May 10, 2022
Blog
Maintaining Data Integrity for Quality and Compliance – Essential Despite Pandemic Disruptions
May 16, 2022
Podcast
RBQM Podcast Series | Episode 3: Staying within the Guardrails: How to Push the Boundaries in a Highly Regulated Industry
Jun 16, 2022
Article
8 things you need to know about eCTDs in China
Jul 1, 2022
Blog
Preparing for the New Era of Hybrid Regulatory Inspections
Jul 11, 2022
Article
EU Orphan Drug Designation – overcoming regulatory challenges
Jul 20, 2022
Video
Cell & Gene Therapies: A Regulatory Update
Jul 22, 2022
Blog
U.S. drug price reform of 2022: What does the Inflation Reduction Act mean for drug manufacturers?
Aug 17, 2022
Article
Relyvrio Approval: Lessons Learned
Oct 31, 2022